Nanfang Hospital, Southern Medical University: Carcinoma, Hepatocellular trials

The registry lists 15 Carcinoma, Hepatocellular studies with Nanfang Hospital, Southern Medical University as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 2 6No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and ImmunotherapyNot yet recruitingNCT07565415Phase 2
• Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related CirrhosisNot yet recruitingNCT07544121Not applicable
• Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingNCT07537777Phase 2
• Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled StudyNot yet recruitingNCT07481032Not applicable
• Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and ImmunotherapyRecruitingNCT07436845
• Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular CarcinomaRecruitingNCT06864221
• A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic SurgeryEnrolling by invitationNCT06647264
• Correlation Study of Lipid Metabolites as Markers of Hepatocellular CarcinomaRecruitingNCT06623474
• Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver CancerActive, not recruitingNCT07230080
• Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT05507632Phase 2
• Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownNCT05171309Phase 2
• Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Phase 2
• Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）Status unknownNCT04806243Phase 2
• Observational Study on Patients With Hepatocellular Carcinoma (HCC)Status unknownNCT04021056
• Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular CarcinomaStatus unknownNCT03285867